Status:
COMPLETED
Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris
Lead Sponsor:
Mayo Clinic
Conditions:
PITYRIASIS RUBRA PILARIS
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to assess the potential effectiveness of Cosentyx in the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Informed subject consent will be obtained from those patients meeting the following inclusion criteria:
- Male and female patients 18 years or older.
- Clinical and/or histopathological diagnosis of PRP
- Candidate for systemic therapy (PASI ≥ 10)
- Body surface area of involvement ≥ 10%
- Good general health as confirmed by medical history
- Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and
- Patients who read and sign an approved informed consent for this study
- Exclusion Criteria
- Patients are to be excluded based on the following criteria:
- Vulnerable study population
- Pregnant or nursing women
- Women planning a pregnancy within the study period
- Human immunodeficiency virus (HIV) positivity
- Known history of adverse reaction to Cosentyx
- Known history of hepatitis B, hepatitis C, or tuberculosis
- Personal or family history of inflammatory bowel disease
Exclusion
Key Trial Info
Start Date :
April 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03342573
Start Date
April 1 2018
End Date
February 1 2022
Last Update
February 24 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
2
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224